Abstract
Trastuzumab increases survival amongst women with human epidermal growth factor receptor (HER)-2 receptor positive metastatic breast cancer, but maternal and fetal risks are associated with advanced disease and its treatment in pregnancy. We present a case of a primigravid with HER-2 positive metastatic breast cancer who received trastuzumab throughout pregnancy. She presented with cerebral metastases, requiring surgical decompression and resection. Reversible oligohydramnios developed during pregnancy. Fetal safety data on trastuzumab in pregnancy is limited, but case reports suggest a recurring pattern of (mostly reversible) oligohydramnios.
© 2011 The Authors. Australian and New Zealand Journal of Obstetrics and Gynaecology © 2011 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
MeSH terms
-
Adult
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Antineoplastic Agents / administration & dosage*
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / secondary
-
Brain Neoplasms / metabolism
-
Brain Neoplasms / secondary
-
Brain Neoplasms / surgery*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / pathology
-
Carcinoma, Ductal, Breast / drug therapy*
-
Carcinoma, Ductal, Breast / metabolism
-
Carcinoma, Ductal, Breast / secondary
-
Craniotomy
-
Decompression, Surgical
-
Female
-
Humans
-
Immunohistochemistry
-
Infant, Newborn
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / secondary
-
Magnetic Resonance Imaging
-
Male
-
Oligohydramnios / etiology
-
Oligohydramnios / physiopathology
-
Pregnancy
-
Pregnancy Complications, Neoplastic*
-
Pregnancy Outcome
-
Radiosurgery
-
Receptor, ErbB-2 / metabolism*
-
Risk Factors
-
Trastuzumab
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Receptor, ErbB-2
-
Trastuzumab